These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 685274)

  • 1. [Geriocaine in the treatment of multiple sclerosis].
    Gawlik L; Mazurek M; Maciejek Z; Berkan L
    Wiad Lek; 1978 May; 31(9):585-8. PubMed ID: 685274
    [No Abstract]   [Full Text] [Related]  

  • 2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of multiple sclerosis with Lyoproper].
    Aschoff JC; Conrad B
    Med Klin; 1971 Jun; 66(30):1055-8. PubMed ID: 4328079
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection.
    Tan FU; Cetinkaya H; Erden E; Ulkatan S; Aydin N
    Hepatogastroenterology; 2002; 49(48):1686-7. PubMed ID: 12397766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute improvement in exacerbating multiple sclerosis produced by intravenous administration of mannitol.
    Stefoski D; Davis FA; Schauf CL
    Ann Neurol; 1985 Oct; 18(4):443-50. PubMed ID: 3000278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Practical method of squint treatment].
    Witusik W
    Klin Oczna; 1975 Aug; 45(8):939-45. PubMed ID: 1160316
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experience with the treatment of multiple sclerosis with proper-myl].
    Briantseva RG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 67(8):1180-2. PubMed ID: 5680529
    [No Abstract]   [Full Text] [Related]  

  • 9. Intrathecal methylprednisolone acetate in multiple sclerosis treatment. Clinical evaluation.
    Mazzarello P; Poloni M; Piccolo G; Cosi V; Pinelli P
    Acta Neurol Belg; 1983; 83(4):190-6. PubMed ID: 6689244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lumbar intrathecal injection of methylprednisolone acetate in the treatment of multiple sclerosis].
    Delzanno GB; Jann G
    Clin Ter; 1969 Jan; 48(2):151-5. PubMed ID: 5409031
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of multiple sclerosis with intrathecally administered methylprednisolone acetate.
    Ringer WA
    J Indiana State Med Assoc; 1968 Sep; 61(9):1213-5. PubMed ID: 5695699
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Our observations regarding the treatment of multiple sclerosis with TFX "Polfa"].
    Fryze W; Obiedziński R
    Neurol Neurochir Pol; 1988; 22(5):475. PubMed ID: 3249619
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of therapeutic effect of intramuscular proper-myl injections in multiple sclerosis].
    Mularek O
    Neurol Neurochir Pol; 1969; 3(4):469-73. PubMed ID: 4897304
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Our contemporary experiences with the intrathecal treatment of multiple sclerosis using depot corticoids. I. Clinical results].
    Hanák L; Zouhar A
    Cesk Neurol Neurochir; 1974 Sep; 37(5):287-92. PubMed ID: 4479028
    [No Abstract]   [Full Text] [Related]  

  • 19. [Biochemical and immunologic research in multiple sclerosis].
    Szabó S
    Acta Neurol Psychiatr Belg; 1968 Sep; 68(9):682-704. PubMed ID: 4180713
    [No Abstract]   [Full Text] [Related]  

  • 20. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.